Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 04 - 05 entities : Bristol-myers squibb company save search
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%
Published: 2022-04-05 (Crawled : 12:00) - biospace.com/
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: -0.04%
H: 1.67%
C: 0.91%
treatment opdivo approval nivolumab urothelial carcinoma
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with...
Published: 2022-04-05 (Crawled : 12:00) - biospace.com/
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: -0.04%
H: 1.67%
C: 0.91%
treatment opdivo approval nivolumab
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with...
Published: 2022-04-05 (Crawled : 12:00) - biospace.com/
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: -0.04%
H: 1.67%
C: 0.91%
treatment opdivo approval nivolumab
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.